Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018

  • ID: 4479933
  • Report
  • 71 pages
  • Global Markets Direct
1 of 5
Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018

Summary:

Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia.

It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy.

Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 1, 8, 4 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Ophthalmology, Gastrointestinal, Genito Urinary System And Sex Hormones, Toxicology, Central Nervous System, Dermatology, Hematological Disorders, Male Health, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Glaucoma, Rheumatoid Arthritis, Non-Alcoholic Steatohepatitis (NASH), Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Arthritis, Asthma, Atopic Dermatitis, Chemotherapy Induced Pain, Chemotherapy Induced Peripheral Neuropathy, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Diabetic Nephropathy, Erectile Dysfunction, Glomerulonephritis, Hepatocellular Carcinoma, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Inflammation, Irritable Bowel Syndrome, Kidney Fibrosis, Lupus Erythematosus, Melanoma, Neuropathic Pain, Non Alcoholic Fatty Liver Disease (NAFLD), Ocular Hypertension, Open-Angle Glaucoma, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis and Pulmonary Fibrosis.

The latest report Adenosine Receptor A3 (ADORA3) - Pipeline Review, H1 2018, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
  • The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Report Coverage

Adenosine Receptor A3 (ADORA3) - Overview

Adenosine Receptor A3 (ADORA3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development

Can-Fite BioPharma Ltd

Adenosine Receptor A3 (ADORA3) - Drug Profiles

ACN-1052 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CF-602 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FM-1302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-1888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LJ-2698 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

namodenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-1650 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-677 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piclidenoson - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Adenosine Receptor A3 (ADORA3) - Dormant Products

Adenosine Receptor A3 (ADORA3) - Discontinued Products

Adenosine Receptor A3 (ADORA3) - Product Development Milestones

Featured News & Press Releases

Feb 28, 2018 : Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson

Feb 22, 2018 : Can Fite Announces the Submission of Safety Reports for Piclidenoson to FDA and other Regulatory Authorities Showing Favorable Safety Profile

Feb 22, 2018 : Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities

Feb 12, 2018 : Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson

Jan 25, 2018 : Can-Fite Receives from Gebro Holdings $2,200,000 Payment as Part of Distribution Agreement for Piclidenoson in 3 European Countries

Dec 18, 2017: Can-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson

Nov 27, 2017: Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson

Oct 30, 2017: Can-Fite Announces Enrollment of First Patient in its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis

Oct 17, 2017: Can-Fite Issued Patent in Korea for Piclidenoson in the Treatment of Psoriasis

Oct 16, 2017: Can-Fite to Present at 2017 AASLD Liver Meeting Conference in Washington, D.C.

Oct 09, 2017: Can-Fite CEO Dr. Pnina Fishman to Present as Expert Speaker at NASH Summit Europe in Frankfurt, Germany on October 12, 2

Aug 23, 2017: Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea

Aug 09, 2017: Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer

Aug 07, 2017: Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson

Jul 17, 2017: Can-Fite's Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting

Appendix

Methodology

Coverage

Secondary Research

Secondary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Can-Fite BioPharma Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Can-Fite BioPharma Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll